SCHEMBL16322198

SCHEMBL16322198

CCn1c(=O)cc(NC(C)c2ccc3c(c2)OCO3)[nH]c1=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ HTT P42858 2/20 0.44
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2B6 P20813 1/20 0.43
▸ KMT2A Q03164 4/20 0.42
▸ MAPT P10636 3/20 0.42
▸ LMNA P02545 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ HPGD P15428 4/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ USP2 O75604 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ PDE1C Q14123 1/20 0.41
▸ POLB P06746 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ OGA O60502 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ TAAR1 Q96RJ0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16322196 1.00 SMN1; SMN2 (0.44) SMN1; SMN2HTTCYP3A4CYP2B6KMT2A
SCHEMBL16321236 0.87 SMN1; SMN2 (0.41) SMN1; SMN2HTTCYP3A4CYP2B6KMT2A
SCHEMBL16321238 0.87 SMN1; SMN2 (0.41) SMN1; SMN2HTTCYP3A4CYP2B6KMT2A
SCHEMBL16322368 0.84 CYP3A4 (0.62) SMN1; SMN2HTTCYP3A4CYP2B6KMT2A
SCHEMBL16322370 0.84 CYP3A4 (0.62) SMN1; SMN2HTTCYP3A4CYP2B6KMT2A
SCHEMBL16324039 0.78 SMN1; SMN2 (0.69) SMN1; SMN2HTTCYP3A4CYP2B6KMT2A
SCHEMBL21667372 0.77 ALDH1A1 (0.66) SMN1; SMN2HTTCYP3A4KMT2AMAPT
SCHEMBL16322050 0.77 HTT (0.53) SMN1; SMN2HTTCYP3A4CYP2B6
SCHEMBL16322048 0.77 HTT (0.53) SMN1; SMN2HTTCYP3A4CYP2B6
SCHEMBL16321646 0.70 SMN1; SMN2 (0.53) SMN1; SMN2HTTCYP3A4CYP2B6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4744664-A2 PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS MyoKardia, Inc. (US) 2026-05-20 — — EP disclosed
US-20240382486-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2024-11-21 — — US disclosed
US-RE50050-E1 Pyrimidinedione compounds MyoKardia, Inc. (US) 2024-07-23 — — US disclosed
US-20230165860-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2023-06-01 — — US disclosed
US-20210346379-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2021-11-11 — — US disclosed
US-20200297726-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2020-09-24 — — US disclosed
EP-3702352-A1 PYRIMIDINEDIONE COMPOUND AGAINST CARDIAC CONDITIONS Myokardia, Inc. (US) 2020-09-02 — — EP disclosed
US-20180311242-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2018-11-01 — — US disclosed
US-20170281626-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2017-10-05 — — US disclosed
US-9585883-B2 Pyrimidinedione compounds MyoKardia, Inc. (US) 2017-03-07 — — US disclosed
EP-3010910-A1 PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS Myokardia, Inc. (US) 2016-04-27 — — EP disclosed
US-20160030428-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2016-02-04 — — US disclosed
US-9181200-B2 Pyrimidinedione compounds MyoKardia, Inc. (US) 2015-11-10 — — US disclosed
US-20140378464-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2014-12-25 — — US disclosed
WO-2014205223-A1 PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS MyoKardia, Inc. (US) 2014-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210346379-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20140378464-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20240382486-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20160030428-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20170281626-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20230165860-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20180311242-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20200297726-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback